| Type | Title | Date Released | |
|---|---|---|---|
6-K | Ping An Biomedical Enters into Patent Purchase Agreement with Future Biotechnology Group for Tumor Cell Technologies | ||
6-K | Ping An Biomedical Co., Ltd. EGM Voting Results on Share Consolidations and Capital Increases | ||
6-K | Planned Acquisition of Three Oncology and Biotechnology Patents Announced for $2 Million to $2.5 Million Consideration | ||
F-3 | October 2026 SHELF | Float: 59,630,000 | ||
6-K | Shareholders to Vote on 40-for-One Consolidation, Capital Increase and Conditional Further Reverse Splits at Extraordinary Meeting | ||
6-K | 1-for-40 Reverse Stock Split Takes Effect October 23, With Split-Adjusted Trading on Nasdaq and Reduced Share Count | ||
DRS | Form DRS | ||
6-K | Ping An Biomedical Co., Ltd. Reports Unaudited Financial Results for the Six Months Ended March 31, 2026 | ||
6-K | Ping An Biomedical Co., Ltd. Announces Change of Independent Registered Public Accounting Firm | ||
6-K | Ping An Biomedical Enters Strategic Partnership with Yuan Sheng Mei Yan to Expand Health Service Channels | ||
6-K | Sale and Purchase Deed for Intellectual Property Assets between Meridian Industries Limited and Multi Ridge (Asia) Limited | ||
6-K | Ping An Biomedical Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement |
